Neurocrine Biosciences | NBIX - SCHULD





SCHULD Veränderung Datum
AbbVie USD 72.86B 5.36B 2026-03
Acadia Pharmaceuticals USD 50.79M 1.39M 2026-03
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
ALKERMES USD 1.58B 1.51B 2026-03
Alnylam Pharmaceuticals USD 1.27B 5.33M 2026-03
Amgen USD 57.32B 2.72B 2026-03
Biogen USD 8.09B 1.53B 2026-06
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Cytokinetics USD 1.29B 4.48M 2026-03
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Exelixis USD 165.93M 3.61M 2026-06
Gilead Sciences USD 22.17B 2.76B 2026-03
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Incyte USD 38.27M 1.16M 2026-06
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Pfizer USD 63.19B 536M 2026-06
Prothena USD 7.65M 1.43M 2026-03
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Repligen USD 690.94M 144.36M 2026-06
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sarepta Therapeutics USD 1.04B 3.08M 2026-03
Teva Pharmaceutical Industries USD 16.91B 187M 2026-03
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.98B 8.9M 2026-06